Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies

NCT01004224 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT01004224
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01004224 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
December 11, 2009
Completion date
October 8, 2018
Enrollment
208 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors with alterations of fgfr1, 2 and or 3, advanced solid tumors with fgfr1 amplication, advanced solid tumors with fgfr2 amplication, advanced solid tumors with fgfr3 mutation, bladder cancer with fgfr3 mutation or fusion, squamous lung cancer with fgfr1 amplification